Use of extracellular matrix and electrical therapy

• US 20060134071A1
• Filed: 12/20/2004
• Published: 06/22/2006
• Est. Priority Date: 12/20/2004
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Salo, Rodney W., Ross, Jeffrey
• Application Number:
  US11/017,237
• Publication Number:
  US 20060134071A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/38 Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
• CPC Class Codes: A61N 1/0587 Epicardial electrode systems; Endocardial electrodes piercing the pericardium
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

The invention provides methods and devices useful for cardiac repair.

Claims

1. A method comprising contacting an isolated extracellular matrix (ECM) support with one or more electrodes, which one or more electrodes are optionally connected to the distal end of one or more connectors.

2. The method of claim 1, wherein the one or more electrodes comprise a plurality of electrodes arranged for delivering electrical energy approximately uniformly over a predetermined area.

3. The method of claim 1, wherein the ECM support is isolated from a non-human vertebrate.

4. The method of claim 1, wherein the surface of the isolated ECM support has a center and a contour, and wherein the one or more electrodes are distributed near the contour of the support.

5. The method of claim 4, wherein a plurality of electrodes is approximately evenly distributed along a loop having a shape approaching the contour of the isolated ECM support.

6. The method of claim 1, wherein one electrode is near the center of the surface of the isolated ECM support.

7. The method of claim 1, wherein the one or more connectors are further connected to a lead.

8. The method of claim 1, wherein the isolated ECM support is contacted with donor cells, one or more cytokines, and/or one or more gene therapy vectors prior to contact with the one or more electrodes.

9. The method of claim 1, wherein the isolated ECM support is contacted with donor cells, one or more cytokines, and/or one or more gene therapy vectors after contacting the isolated ECM support with the one or more electrodes.

10. The method of claim 8 or 9 wherein the donor cells are stem cells.

11. The method of claim 8 or 9 wherein the donor cells are cardiomyocytes.

12. The method of claim 8 or 9 wherein the donor cells are genetically modified cells.

13. The method of claim 1, wherein the electrodes are embedded in the isolated ECM support.

14. The method of claim 1, wherein the electrodes are affixed to the surface of the isolated ECM support.

15. The method of claim 8 or 9 wherein one cytokine is G-CSF, SCF, HGF or IGF.

16. One or more electrodes comprising isolated ECM prepared by the method of claim 1.

17. A method, comprising:

introducing to a mammal an implantable device comprising a sensor to sense a physiological signal indicative of a predetermined cardiac condition, one or more electrodes comprising isolated ECM, and a generator coupled to the sensor and the one or more electrodes, the generator adapted to control an electrical therapy; and

applying electrical therapy, so as to modulate remodeling in the mammal after cardiac injury based on at least the sensed physiological signal.

18. The method of claim 17, wherein cardiac function is enhanced.

19. The method of claim 17, further comprising administering donor cells, one or more cytokines and/or one or more gene therapy vectors.

20. The method of claim 19, wherein the donor cells are stem cells.

21. The method of claim 19, wherein the donor cells are cardiomyocytes.

22. The method of claim 19, wherein the donor cells are genetically modified cells.

23. The method of claim 19, wherein the donor cells are administered prior to introduction of the implantable device.

24. The method of claim 19, wherein one cytokine is G-CSF, SCF, HGF or IGF.

25. The method of claim 17, wherein the isolated ECM further comprises donor cells.

26. The method of claim 17, wherein the isolated ECM further comprises one or more cytokines.

27. The method of claim 17, wherein the isolated ECM further comprises one or more gene therapy vectors.

28. A method comprising:

delivering electrical therapy to cardiac tissue of a mammal using an implantable pulse generator having isolated ECM applied thereto, wherein the electrical therapy enhances the regenerative and/or repair properties of the isolated ECM.

29. The method of claim 28, wherein the isolated ECM further comprises donor cells, one or more cytokines, and/or one or more gene therapy vectors.

30. The method of claim 28, further comprising administering donor cells, one or more cytokines, and/or one or more gene therapy vectors.

31. The method of claim 29 or 30 wherein the donor cells are stem cells.

32. The method of claim 29 or 30 wherein the donor cells are cardiomyocytes.

33. The method of claim 29 or 30 wherein the donor cells are genetically modified cells.

34. The method of claim 29 or 30 wherein one cytokine is G-CSF, SCF, HGF, or IGF.

35. The method of claim 28, wherein the ECM is isolated from small intestine submucosa or urinary bladder submucosa.

36. The method of claim 28, wherein the electrical therapy is pacing therapy.